Gatehouse Bio, a pioneer in next-generation therapeutics, and AstraZeneca, a global science-led biopharmaceutical company, are collaborating to explore the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio's Artificial Intelligence powered platform, it was reported yesterday.
Gatehouse Bio's 'sRNAlytics platform' identifies novel small RNA (sRNA) signatures and illuminates molecular pathways correlated to and potentially driving disease.
Dr David W. Salzman, CEO and chief scientist, Gatehouse Bio, said, 'Our annotation library of over 1.4M small RNA features coupled with our biology-directed machine learning algorithms enable us to see signal where others have only seen noise.'
The company is collaborating with top global drug developers to incorporate their technology into discovery, research, and development programs.
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD